Drug insight: cyclo-oxygenase-2 inhibitors--a critical appraisal (Q28222352)

Nature Clinical Practice Rheumatology

Europe PubMed Central

title

Drug insight: cyclo-oxygenase-2 inhibitors--a critical appraisal (English)

0 references

author name string

Burkhard Hinz

series ordinal

1

0 references

Bertold Renner

series ordinal

2

0 references

Kay Brune

series ordinal

3

0 references

language of work or name

English

0 references

publication date

October 2007

0 references

published in

0 references

volume

3

0 references

issue

10

0 references

page(s)

552-60; quiz 1 p following 589

0 references

cites work

Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021

Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021

Up-regulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021

The coxibs, selective inhibitors of cyclooxygenase-2.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021

Cyclooxygenase-2--10 years later

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021

The development of COX2 inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021

Comparison of inhibitory effects of meloxicam and diclofenac on human thromboxane biosynthesis after single doses and at steady state

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021

Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenac

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021

Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021

Investigation of the pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021

Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021

More pronounced inhibition of cyclooxygenase 2, increase in blood pressure, and reduction of heart rate by treatment with diclofenac compared with celecoxib and rofecoxib

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021

Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021

Pharmacokinetics of lumiracoxib in plasma and synovial fluid

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021

Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021

Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021

Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021

Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021

Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021

A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021

Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021

Mechanisms of aspirin sensitivity

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021

Celecoxib in patients with asthma and aspirin intolerance. The Celecoxib in Aspirin-Intolerant Asthma Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021

Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021

Safety of a specific COX-2 inhibitor in aspirin-induced asthma

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021

The safety of celecoxib in patients with aspirin-sensitive asthma

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021

Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021

Celecoxib for the prevention of colorectal adenomatous polyps

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021

Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021

Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021

Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021

Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021

Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021

Balancing prostanoid activity in the human vascular system

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021

Regulation of thrombomodulin expression in human vascular smooth muscle cells by COX-2-derived prostaglandins

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021

Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021

Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021

Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021

Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021

Cyclooxygenase inhibitors and the antiplatelet effects of aspirin

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021

Effect of ibuprofen on cardioprotective effect of aspirin

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021

Dipyrone elicits substantial inhibition of peripheral cyclooxygenases in humans: new insights into the pharmacology of an old analgesic

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021

Non-narcotic analgesic dose and risk of incident hypertension in US women

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021

Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021

Selective cyclooxygenase-2 inhibitors: similarities and differences

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021

A validated high-performance liquid chromatographic assay for determination of lumiracoxib in human plasma

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0619

7 January 2021